SAVA Stuck At 382
It's interesting to see what happens after plotting out fib lines sometimes. 
SAVA, for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of.
"The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: AMEX:ANVS), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
SAVA, for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of."The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: AMEX:ANVS), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.